All In MedTech

FDA Clearance Tracker · P000021-S013

DIMENSION VISTA TPSA FLEX REAGENT CARTRIDGE

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 19, 2010 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 19, 2010

Approved

Time to decision

533 days

Received Dec 2, 2008. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P000021-S013
Device name
DIMENSION VISTA TPSA FLEX REAGENT CARTRIDGE
Applicant location
Newark, DE
Received
Dec 2, 2008
Decided
May 19, 2010
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P000021

Device type

Device class
Class III

Every decision under product code MTF

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE FOLLOWING CHANGES:1) DETECTION TECHNOLOGY FROM SPECTROPHOTOMETRY TO CHEMILUMINESENCE2) APPROPRIATE REAGENT PROCESS CHANGES TO ACCOMMODATE CHEMILUMINESENCE DETECTION3) USAGE ON THE DIMENSION VISTA 1500 SYSTEM4) USAGE ON THE DIMENSION VISTA 3000T SYSTEM WHICH CONSISTS OF TWO DIMENSION VISTA1500 SYSTEMS CONNECTED BY A SAMPLE TRACK TRANSPORT MECHANISM5) USAGE ON THE DIMENSION VISTA 1500 SYSTEM CONNECTED TO THE STREAMLAB ANALYTICALWORKCELL LABORATORY AUTOMATION SYSTEM6) THE NEW DIMENSION VISTA PSA CALIBRATOR FOR USE WITH THE DIMENSION VISTA TPSA AND FPSA METHODS.THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME DIMENSION VISTA TPSA FLEXREAGENT CARTRIDGE AND IS INDICATED FOR THE FOLLOWING USES:THE TPSA METHOD IS AN IN VITRO DIAGNOSTIC TEST FOR THE QUANTITATIVE MEASUREMENT OF TOTAL PROSTATESPECIFIC ANTIGEN (PSA) IN HUMAN SERUM AND PLASMA ON THE DIMENSION VISTA SYSTEM: 1) AS AN AID IN THE DETECTION OF PROSTATE CANCER WHEN USED IN CONJUNCTION WITH DIGITAL RECTAL EXAM (DRE) IN MEN 50 YEARS OR OLDER. PROSTATE BIOPSY IS REQUIRED FOR DIAGNOSIS OF CANCER. 2) AS AN AID IN THEMANAGEMENT (MONITORING) OF PROSTATE CANCER PATIENTS.THE DIMENSION VISTA PSA CALIBRATOR WILL BE MARKETED SEPARATELY FOR USE WITH THE DIMENSIONVISTA TPSA FLEX REAGENT AND IS INDICATED FOR THE CALIBRATION OF TOTAL (TPSA) AND FREE (FPSA) PROSTATE SPECIFIC ANTIGEN METHODS ON THE DIMENSION VISTA SYSTEMS.

Source documents

Other decisions for Siemens Healthcare Diagnostics

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.